LGVN Stock Overview A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Longeveron Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Longeveron Historical stock prices Current Share Price US$1.81 52 Week High US$13.16 52 Week Low US$0.77 Beta 0.38 1 Month Change -12.56% 3 Month Change 1.69% 1 Year Change -85.86% 3 Year Change -98.01% 5 Year Change n/a Change since IPO -97.56%
Recent News & Updates
Forecast to breakeven in 2027 Dec 31
Consensus estimates of losses per share improve by 16% Nov 26
Consensus EPS estimates fall by 19% Nov 20
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14
Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024 Nov 12
Longeveron Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05 See more updates
Forecast to breakeven in 2027 Dec 31
Consensus estimates of losses per share improve by 16% Nov 26
Consensus EPS estimates fall by 19% Nov 20
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14
Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024 Nov 12
Longeveron Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Longeveron Inc. Presents Lomecel-B™? Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) Oct 30
Longeveron Inc. Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) Sep 04
Consensus estimates of losses per share improve by 12% Aug 28
Price target decreased by 31% to US$8.32 Aug 27
Consensus revenue estimates fall by 14% Aug 21
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 16
Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 06
Consensus revenue estimates increase by 21% Jul 31
Price target decreased by 10% to US$11.32 Jul 30
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) Jul 29
Consensus EPS estimates upgraded to US$3.42 loss Jul 22 Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million. Longeveron Inc. has filed a Follow-on Equity Offering. Jul 19
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease Jul 17
Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease Jul 10
Longeveron Inc. Elects Neha Motwani to Its Board of Directors Jul 09
Longeveron Inc. Appoints Roger Hajjar to Board of Directors Jul 08
Price target decreased by 12% to US$12.30 Jun 19
Consensus EPS estimates upgraded to US$3.91 loss Jun 19
Longeveron Inc., Annual General Meeting, Jul 02, 2024 May 23
Consensus revenue estimates increase by 931% May 21
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 16
Less than half of directors are independent May 15
Longeveron Inc. Announces Board Changes May 11
Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024 May 03
Consensus EPS estimates upgraded to US$5.85 loss May 02
Price target decreased by 48% to US$37.50 Apr 17
New major risk - Share price stability Apr 16 Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million. Apr 12
New major risk - Shareholder dilution Apr 09
New major risk - Market cap size Mar 21
Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance Mar 21 Longeveron Inc. has filed a Follow-on Equity Offering. Mar 20
Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Mar 08
Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Mar 07
Full year 2023 earnings: EPS misses analyst expectations Feb 29
Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024 Feb 22 Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million. Dec 23
Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million. Dec 22
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease Dec 21
Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association Nov 12
Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023 Nov 04
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's Oct 26
New minor risk - Shareholder dilution Oct 13
Consensus revenue estimates increase by 41% Oct 08
Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease Oct 06
Director exercised options to buy US$70k worth of stock. Sep 15
New major risk - Revenue size Aug 13
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 13
Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome Aug 12
Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023 Aug 08 Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023
Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer Jul 06
High number of new directors Jul 01
Longeveron Inc. Approves Bord Appointments Jun 14
Longeveron Inc. Announces Resignation of James Clavijo as CFO Jun 07
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 14
Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome May 10
Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023 May 09
Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021) Mar 10
Price target decreased to US$15.50 Jan 10
Longeveron Provides Corporate Update Jan 07
Consensus forecasts updated Nov 21
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? Nov 17
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 16
High number of new directors Nov 16
Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease Nov 11
Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Longeveron Inc.: A New Approach To Treat Alzheimer's Oct 09
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B(TM) Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants Sep 01
Longeveron spikes after FDA’s Fast Track Designation for lead candidate Aug 31
Consensus revenue estimates fall by 12% Aug 19
Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.26 loss in 2Q 2021) Aug 12
Longeveron Inc. to Report Q2, 2022 Results on Aug 12, 2022 Aug 09
Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth? Jul 15
Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference Jul 07
Director notifies of intention to sell stock Jul 01
CFO & Treasurer recently sold US$305k worth of stock Jun 09
Director recently sold US$153k worth of stock May 26 Shareholder Returns LGVN US Biotechs US Market 7D 4.6% 1.9% 0.7% 1Y -85.9% -6.6% 23.9%
See full shareholder returns
Return vs Industry: LGVN underperformed the US Biotechs industry which returned -6.6% over the past year.
Return vs Market: LGVN underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is LGVN's price volatile compared to industry and market? LGVN volatility LGVN Average Weekly Movement 9.8% Biotechs Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: LGVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LGVN's weekly volatility has decreased from 28% to 10% over the past year.
About the Company Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome.
Show more Longeveron Inc. Fundamentals Summary How do Longeveron's earnings and revenue compare to its market cap? LGVN fundamental statistics Market cap US$28.19m Earnings (TTM ) -US$26.57m Revenue (TTM ) US$1.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LGVN income statement (TTM ) Revenue US$1.85m Cost of Revenue US$500.00k Gross Profit US$1.35m Other Expenses US$27.92m Earnings -US$26.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.79 Gross Margin 73.00% Net Profit Margin -1,434.67% Debt/Equity Ratio 0%
How did LGVN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 22:55 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Longeveron Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju H.C. Wainwright & Co. Boobalan Pachaiyappan H.C. Wainwright & Co. Jason McCarthy Maxim Group
Show 3 more analysts 
